HAS's two-tier PNH assessment gave ravulizumab first-line SMR-important status and iptacopan an ASMR III rating restricted to second-line use, splitting the CEPS price negotiation into two structurally different tracks.
France's HTA architecture assesses PNH therapies on two separate scales. SMR (Service Médical Rendu), the actual medical benefit rating that sets the statutory reimbursement rate, rated ravulizumab (Ultomiris) 'important', and HAS positions it as first-line therapy, citing its every-eight-week dosing advantage over eculizumab's every-two-week schedule. ASMR (Amélioration du Service Médical Rendu), the added-value rating that anchors CEPS price negotiation, rated iptacopan (Fabhalta) ASMR III, a moderate improvement, in the Commission de la Transparence opinion of 9 October 2024 — but restricted that rating to second-line use only, for adult patients with persistent hemolytic anemia (haemoglobin below 10 g/dL) after at least six months on a C5 complement inhibitor.
That two-tier split shapes CEPS's price negotiation differently for each drug. Ravulizumab's published price, €14,988.66 for the 1100mg vial and €4,087.82 for the 300mg vial, applies across an unrestricted first-line population that never had to argue its way past a prior-treatment gate. Iptacopan's published price, €29,590.96 per box of 56 capsules, was negotiated against a target population the manufacturer itself estimated at only 270 patients nationally — a genuinely small commercial base for CEPS to apply its standard ASMR-anchored, European-reference-price, and volume-forecast negotiation levers against. A separate CEESP economic opinion of 5 December 2024 assessed iptacopan's efficiency at the claimed price and found a very high incremental cost-effectiveness ratio against a mixed comparator arm of C5 inhibitors.
France's PNH HTA status by agent — ravulizumab's first-line SMR-important rating versus iptacopan's second-line-restricted ASMR III
| Agent | SMR | ASMR | Position | Published Price |
|---|---|---|---|---|
| Ultomiris (ravulizumab) | Important | — | First-line | €14,988.66 (1100mg) / €4,087.82 (300mg) |
| Fabhalta (iptacopan) | — | III (moderate) | Second-line only (Hb <10 g/dL, ≥6mo prior anti-C5) | €29,590.96 per box of 56 capsules |
Sources: HAS Commission de la Transparence, Avis FABHALTA (iptacopan), 9 octobre 2024 (SMR/ASMR); HAS CEESP, Avis économique FABHALTA (iptacopan), 5 décembre 2024 (efficience); HAS Commission de la Transparence, ULTOMIRIS (ravulizumab); French public medicines database (base-donnees-publique.medicaments.gouv.fr).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The SMR mechanism (reimbursement-rate eligibility) versus ASMR (price-negotiation anchor)
- how each drug scored on each scale and why
Delivers
- The manufacturer's own population estimate
- how CEPS's ASMR-anchored, small-population negotiation dynamics work
- the pricing precedent this sets
Delivers
- Ravulizumab's SMR important rating and first-line comparator status
- the pricing and access bar a new entrant competing for first-line position must clear
Custom brief delivered in 72 hours.
Commission this briefWhat's inside
- How SMR sets reimbursement eligibility and ASMR anchors CEPS price negotiation
- Where ravulizumab and iptacopan sit on each scale
- The every-8-week dosing advantage HAS cited
- First-line comparator implications for new entrants
- The Hb<10g/dL, ≥6-month prior anti-C5 eligibility gate
- The 5 December 2024 HAS economic opinion
- Published reimbursement prices for both agents
- Small-population specialty pricing dynamics under CEPS's negotiation levers
- How France's published prices, €14,988.66/€4,087.82 for ravulizumab and €29,590.96 for iptacopan, feed other countries' international reference-pricing baskets
- Why CEPS's European-reference-price negotiation lever adds cascade risk beyond France's own SMR/ASMR ratings
- Why ravulizumab's unrestricted first-line SMR-important status contrasts with iptacopan's second-line-only ASMR III restriction
- How the small 270-patient iptacopan population and ravulizumab's broader first-line population define two distinct competitive footholds in France
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources — HAS Commission de la Transparence opinions and live CEPS pricing documentation, not secondary summaries. Findings are independently verified before inclusion.
PNH France Payer & HTA sources: HAS Commission de la Transparence opinion for iptacopan (9 October 2024, SMR/ASMR ratings); HAS CEESP economic opinion for iptacopan (5 December 2024, efficiency assessment); HAS Commission de la Transparence documentation for ravulizumab; French public medicines database for reimbursement pricing.
- Iptacopan's ASMR III rating and second-line restriction verified against the live HAS Commission de la Transparence economic opinion
- Ravulizumab's SMR important rating and first-line status verified against HAS Commission de la Transparence documentation
- Published reimbursement prices for both agents verified against the French public medicines database
Frequently asked questions
Commission this assessment
AXLRx PNH Payer & HTA — France is built for market access and payer teams that need a rigorous characterisation of the French SMR/ASMR framework and CEPS pricing dynamics. Custom brief in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.